IMUX

Immunic Stock Analysis

AI Rating

Good
  • Quality2/10
  • Growth↑ 5/10
  • Value↑ 9/10
Immunic sales and earnings growth
IMUX Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 46.58%
  • FCF Y/Y↓ 1.70%
Immunic gross and profit margin trends
IMUX Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↑ 895.85%
Immunic net debt vs free cash flow
IMUX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Immunic stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks